Skip to main content

Skip to main content

Home
About Cerus
Products
Investors
Learn
Life at Cerus
- Careers

Investor Overview
Press Releases
Events & Presentations
- Annual Meeting
- Events & Webcasts
Financial Information
Governance
- Corporate Governance
- Corporate Actions
Resources
- Email Subscription
- Investor Contacts

Site Search

Cerus.com
The corporate website includes broad information about Cerus, resources for investors, and career opportunities.
INTERCEPT-USA.com
For residents of the United States – Blood centers and transfusion services will find topics related to the production of pathogen reduced products.
HCP.INTERCEPT-USA.com
For residents of the United States – Hospital blood banks and healthcare practitioners will find content related to clinical topics, implementation, and education.
INTERCEPT-Canada.com
For residents of Canada – Specific information for pathogen reduced platelets and plasma including package inserts.
INTERCEPTBloodSystem.com
Visitors in Europe, the Middle East, Africa, Asia or Latin America will find information about pathogen inactivated platelets and plasma.
INTERCEPT-Cryoprecipitation.com
For residents of the United States – Learn more about the INTERCEPT® Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

Event Details

Investor Overview
Press Releases
Events & Presentations
- Annual Meeting
- Events & Webcasts
Financial Information
Governance
- Corporate Governance
- Corporate Actions
Resources
- Email Subscription
- Investor Contacts

Home
About Cerus
Products
Investors
News and Events

Cerus Websites

Cerus.com
INTERCEPT-USA.com
HCP.INTERCEPT-USA.com
INTERCEPT-Cryoprecipitation.com
INTERCEPT-Canada.com
INTERCEPTBloodSystem.com

Cerus Corporation Third Quarter 2022 Earnings Call

11/03/2022 4:30 PM ET

Webcast (opens in new window)

Global Headquarters

1220 Concord Avenue

Concord, CA US 94520

+1 925.288.6000

European Headquarters

Stationsstraat 79-D

3811 MH Amersfoort, Netherlands

+31 (0) 33 49 60 600

Cookie Notice
Legal
Privacy Policy

Copyright (c) Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. InterSol and Amicus are trademarks of Fenwal, Inc.

About Cerus

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

Powered By Q4 Inc. 5.176.0.2 (opens in new window)